While CRISPR grabs headlines and mRNA dominates headlines, the real action in biotech is happening in the electroporation chamber. Maxcyte isn't building therapies—it's building the machines that make them possible.

"Maxcyte isn't chasing the $100B therapy market—it's selling the shovels to everyone mining it."

• Scalability from research to commercial production without changing platforms
• High-efficiency electroporation that maintains cell viability (critical for therapeutic success)
• Regulatory-ready systems that satisfy FDA and EMA requirements
• Open architecture that works with any cell therapy protocol

What makes Maxcyte uniquely positioned is their focus on the entire cell therapy workflow. While competitors chase specific therapeutic applications, Maxcyte provides the universal hardware layer. Their ExPERT™ instruments aren't optimized for one type of cell—they're engineered to handle the diversity of the entire cell therapy pipeline, from rare natural killer cells to engineered myeloid therapeutics.